Evicenter
P&T meetings

Zipalertinib (CLN-081)

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417
Manufacturer
Taiho Oncology
Regulatory submission
NDA submitted February 2026
Launch
Not announced
Last updated
75 sources

Product information and disease descriptionProduct descriptionProduct information

Access and distribution

2 evidence topics · 2 sources

Commercialization

“Taiho will commercialize zipalertinib.” (opens the source at this quote in a new tab)

Pre-approval access: Taiho’s general expanded-access policy

“Taiho accepts requests for pre‑approval access to investigational cancer medicines from physicians only.” (opens the source at this quote in a new tab)

“does not guarantee access to any investigational product.” (opens the source at this quote in a new tab)

Anticipated commercial distribution strategy and patient support programs

No evidence found.